With the integration of deep learning technology, ContextVision takes digital radiography to new levels with its latest image enhancement platform, Altumira(TM).
After over 8 years as the CEO at ContextVision, Anita Tollstadius has informed the Board of Directors that she wishes to retire during 2019, to spend more time with her family.
Stockholm, September 24th, 2018 – An update on ContextVision has been published in the Swedish online magazine Investeringstipset (in Swedish only). Please find a link here. For further information, please contact ContextVision’s CEO, Anita Tollstadius, at +46 70 337 30 26 or visit www.contextvision.com. About ContextVision ContextVision is a medical technology software company that specializes […]
September 6, 2018, – ContextVision is making their second appearance in the field of digital pathology at ECP 2018, the 30th European Congress of Pathology, September 8–12 in Bilbao, Spain. Here, they will be introducing and demonstrating their upcoming product INIFY™ Prostate, a new decision support tool based on artificial intelligence and deep learning.
ContextVision recently made their first appearance in the field of digital pathology at ECDP/NDP 2018 – the 14th European Congress on Digital Pathology and the 5th Nordic Symposium on Digital Pathology, held in Helsinki, Finland, end of May.
June 20, 2018 – The installation was made through the fully integration with the Hospital's Laboratory Information System at the pathology department at Ospedale Cannizzaro in Catania, Italy.
May 28, 2018, – ContextVision will be introducing their upcoming product INIFY™ Prostate, a new decision support tool based on artificial intelligence and deep learning.
May 18th, 2018 - ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, and its academic partners at Uppsala University and Uppsala Hospital have been awarded a grant from Sweden's innovation agency, Vinnova, for a continuation of a research program within digital pathology research. The company has already achieved very encouraging results in preliminary studies. The grant will cover costs at the hospital and at Uppsala University.